RICHMOND, Calif., June 15, 2017 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (NASDAQ:EKSO), an industry leader in exoskeleton technology for medical and industrial use, today announced a collaboration with four leading rehabilitation facilities to establish Centers of Robotic Excellence to help further advance the use of innovative exoskeleton technology for mobility impaired patients.
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/9adfbc05-aa7d-43ca-b76e-fc0ea2b56b9b
As early adopters of state-of-the-art exoskeleton technology, the centers have committed to provide peer-to-peer support as reference sites to train other facilities interested in becoming proficient in innovative approaches to rehabilitation.
The centers include:
“Collaborating with leaders in the rehabilitation community is key to building clinical support on the benefits of exoskeletons to aid early mobility for stroke & spinal cord injury,” said Thomas Looby, president and chief executive officer of Ekso Bionics. “We are proud to work with these visionaries who are dedicated to helping patients with recovery and to provide quantifiable insights into the strides they’re making walking with an exoskeleton.”
Christina Kwasnica, M.D., medical director for the Barrow Neuro Rehabilitation Center, notes, “The robotic device allows us to get patients up on their feet earlier. The gains we see are overwhelming and the positive effects on a patient’s mood and motivation is unbelievable.”
Each center will also work with Ekso Bionics to aid in research and development efforts. The Centers of Excellence will gather clinical evidence and measurable results on rehabilitation with EksoGTTM and create research protocols for proving standard of care for exoskeletons for rehabilitation.
“As an early adopter of the EksoGT, we look forward to mentoring our peers and sharing our knowledge so that more patients can benefit from this life-changing technology,” said Frank Hyland, M.S., P.T., executive director of Good Shepherd Rehabilitation Network and administrator of Good Shepherd Rehabilitation Hospital. “Good Shepherd has experienced the economic advantage firsthand with a significant return on investment, increased market share growth, and a value proposition that also benefits patients and payers. EksoGT is now the cornerstone of our rehabilitation program and has helped our patients take 3 million steps and counting.”
To learn more about the Centers of Excellence and the EksoGT, visit http://eksobionics.com/eksohealth/centers-of-excellence/.
About Ekso Bionics®
Ekso Bionics is a leading developer of exoskeleton solutions that amplify human potential by supporting or enhancing strength, endurance and mobility across medical, industrial and defense applications. Founded in 2005, the company continues to build upon its unparalleled expertise to design some of the most cutting-edge, innovative wearable robots available on the market. Ekso Bionics is the only exoskeleton company to offer technologies that range from helping those with paralysis to stand up and walk, to enhancing human capabilities on job sites across the globe, to providing research for the advancement of R&D projects intended to benefit U.S. defense capabilities. The company is headquartered in the Bay Area and is listed on the Nasdaq Capital Market under the symbol EKSO. For more information, visit: www.eksobionics.com.
About Ekso GT™
Ekso GT™ is the first exoskeleton cleared by the FDA for use with stroke and spinal cord injuries from L5 to C7. The EksoGT with SmartAssist™ software is the only exoskeleton available for rehabilitation institutions that can provide adaptive amounts of power to either side of the patient’s body, challenging the patient as they progress through their continuum of care. The suit’s patented technology provides the ability to mobilize patients earlier, more frequently and with a greater number of high intensity steps. To date, this device has helped patients take more than 70 million steps in over 130 rehabilitation institutions around the world.
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements may include, without limitation, statements regarding (i) the plans and objectives of management for future operations, including plans or objectives relating to the design, development and commercialization of human exoskeletons, (ii) estimates or projection of financial results, financial condition, capital expenditures, capital structure or other financial items, (iii) the Company's future financial performance and (iv) the assumptions underlying or relating to any statement described in points (i), (ii) or (iii) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to obtain adequate financing to fund the Company's operations and necessary to develop or enhance our technology, the significant length of time and resources associated with the development of the Company's products, the Company's failure to achieve broad market acceptance of the Company's products, the failure of our sales and marketing organization or partners to market our products effectively, adverse results in future clinical studies of the Company's medical device products, the failure to obtain or maintain patent protection for the Company's technology, failure to obtain or maintain regulatory approval to market the Company's medical devices, lack of product diversification, existing or increased competition, and the Company's failure to implement the Company's business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC. To learn more about Ekso Bionics please visit us at www.eksobionics.com. The Company does not undertake to update these forward-looking statements.
The photo is also available at Newscom, www.newscom.com, and via AP PhotoExpress.
Media Contact: Carrie Yamond 917-371-2320 firstname.lastname@example.org Investor Contact: David Carey 212-867-1768 email@example.com